The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000494336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
7/04/2026
Date registered
Help: Date registered
21/04/2026
Date last updated
Help: Date last updated
28/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The Effect of an Ultra Processed Diet on Metabolic Health in Endurance Athletes
Scientific title
The Effect of an Ultra Processed Diet on Metabolic Health Markers in Highly Trained Endurance Athletes
Additional trial identifiers [1] 316939 0
Nil
Universal Trial Number (UTN)
Trial acronym
Super TRAIN Me
Related trial records

Health condition
Health condition(s) studied:
Dyslipidaemia 341374 0
Cardiovascular disease risk 341390 0
Metabolic health 341393 0
Condition category
Condition code
Cardiovascular 337436 337436 0 0
Normal development and function of the cardiovascular system
Blood 337437 337437 0 0
Other blood disorders
Metabolic and Endocrine 337438 337438 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
16 male and female endurance-based athletes (triathletes and cyclists; training > 12 h/week), aged 18-45 years, will be recruited for this single-arm study design. All participants will complete a normal habitual diet period (28 days) before then competing an ultra-processed food (UPF) diet (28 days). Screening and pre-testing (Visit 1) for the study will include; blood lipid screen, blood pressure, Exercise & Sports Science Australia (ESSA) Adult Pre-Exercise Screening Tool (APSS), Eating Disorder Examination Questionnaire, a brief dietitian interview, and a ramp protocol test for the determination of maximal oxygen uptake (VO2max).

On the morning of Visit 2 (baseline testing), participants will arrive at the Australian Catholic University (ACU) Melbourne campus following an overnight fast to complete a dual X-ray absorptiometry (DXA) scan to assess body composition, provide a blood sample (~21 mL; see outcome measures below), undertake blood pressure measures, and complete three questionnaires; Recovery-Stress Questionnaire for Athletes (RESTQ-Sport); Pittsburgh Sleep Quality Index (PSQI) and Gastrointestinal Symptom Rating Scale (GSRS). Following the completion of these surveys, participants will complete a maximal fat oxidation exercise test (FATmax). Following this, participants will undergo a mixed meal tolerance test (MMTT), consisting of the consumption of a mixed meal of a known nutritional composition, followed by repeated blood samples (~42 mL total) for 2 h post ingestion to determine insulin sensitivity and whole-body glucose handling. Upon completion of baseline testing, participants will consume their habitual diet in free-living conditions (i.e., ad libitum without dietary restrictions) for 28 d. Participants will be asked to provide photo logs of all food and fluid intake during the 28 d habitual diet period using a commercial mobile phone app (Cronometer) that will be programmed to share data with the research team while hiding real time feedback from the user. Energy and macronutrient intake will be assessed by a registered dietitian with the aid of AI recognition of food photos. On Day 14 (Visit 3), participants will report to the laboratory and provide a blood sample (~21 mL) and undergo blood pressure measurement before completing the questionnaires (RESTQ-Sport, GSRS and PSQI). Following the 28-d habitual diet period (Day 29, Visit 6), participants will report to the lab after an overnight fast and repeat the DXA scan, provide a blood sample (~21 mL), undertake blood pressure measures, an MMTT, complete a battery of questionnaires (PSQI, RESTQ-SPORT, and GSRS) followed by a FATmax. Immediately, following Visit 4, all participants will then complete 28 d of a UPF diet. Participants will be required to consumed three meals (breakfast, lunch, dinner) each day and food items must be selected from the McDonald’s or KFC food and drink menu (ad libitum until satiety). Participants will be supplied with unique login details to the McDonalds and KFC app in order for the research team to track what was purchased. Participants will also be requested to photograph any food items that were not consumed which will be uploaded onto Cronometer. Additional UPF snacks (e.g., gummy sweets, energy bars, energy gels) will be provided during the UPF dietary condition to aid intra and between-workout fueling and recorded on Cronometer. Dietary compliance will be defined as exclusive adherence to the designated menu on a minimum of 6 out of 7 days per week for the 4-week dietary intervention. Participants will be required to attend the ACU laboratory at the same timepoints (Visit 5 on day 14, Visit 6 on day 29) for follow-up testing as outlined above.

Throughout the entire intervention period, weekly health check-ins via text message will be used to assess compliance with diet and exercise training. Diet tracking and food provisions will be managed by qualified clinical dietitian. Participants will be asked to maintain their current training regime and to record daily exercise training (via the TrainingPeaks app). Participants will also wear an Oura Ring throughout the 8-week trial to assess heart rate variability.
Intervention code [1] 333659 0
Lifestyle
Intervention code [2] 333660 0
Treatment: Other
Description of the comparator or control
The 28-day habitual diet phase serves as the within-participant comparator for this study. During this phase, participants maintain their usual self-selected diet with no dietary restrictions imposed for a period of 28 days. All food and beverage intake is self-selected and recorded daily using the Cronometer mobile application. Participants continue their regular endurance exercise training throughout this period, logging all sessions on the TrainingPeaks application.
Outcome measures collected during the habitual diet phase serve as the baseline comparator against which changes observed during the subsequent 28-day ultra-processed food dietary intervention phase are assessed.
Control group
Active

Outcomes
Primary outcome [1] 344959 0
Changes to high-density lipoprotein (HDL) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [1] 344959 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56). Visit 6 (Day 56; post ultra-processed food diet) is considered the primary timepoint.
Secondary outcome [1] 459916 0
Changes to total cholesterol under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [1] 459916 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [2] 459917 0
Change in Interleukin-6 (IL-6) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [2] 459917 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [3] 459954 0
Change in Leptin under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [3] 459954 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [4] 459955 0
Changes to Maximal fat oxidation (FATmax), under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [4] 459955 0
FATmax will be measured at 3 timepoints; visits 2, 3 and 6 (days 1, 28 and 56).
Secondary outcome [5] 459956 0
Mixed meal tolerance test will be used to evaluate how an ultra-processed food diet effects postprandial glycaemic and insulinaemic responses to a mixed macronutrient meal.
Timepoint [5] 459956 0
The mixed meal tolerance test will be measured at 3 timepoints; visits 2, 3 and 6 (days 1, 28 and 56).
Secondary outcome [6] 459957 0
Changes to total body composition using dual x-ray absorptiometry (DXA) scan following adherence to an ultra-processed food diet compared to a habitual diet phase.
Timepoint [6] 459957 0
Total body composition will be measured at 3 timepoints; visits 2, 3 and 6 (days 1, 28 and 56).
Secondary outcome [7] 459958 0
Changes to resting blood pressure following adherence to an ultra-processed food diet compared to a habitual diet phase.
Timepoint [7] 459958 0
Resting blood pressure will be measured at 5 timepoints: visits 2-6 (Days 1, 14, 29, 43, 56).
Secondary outcome [8] 459959 0
Changes to recovery and stress, using the Recovery-Stress Questionnaire for Athletes (RESTQ-Sport), following adherence to an ultra-processed food diet compared to the habitual diet phase. Stress and recovery is assessed as a composite outcome, embedded within the RESTQ-Sport questionnaire.
Timepoint [8] 459959 0
RESTQ-Sport will be measured at 5 timepoints: visits 2-6 (Days 1, 14, 29, 43, 56).
Secondary outcome [9] 459964 0
Changes to perceived gastrointestinal symptoms using the Gastrointestinal Symptoms Rating Scale (GSRS) following adherence to an ultra-processed food diet compared to a habitual diet phase.
Timepoint [9] 459964 0
GSRS will be measured at 5 timepoints: visits 2-6 (Days 1, 14, 29, 43, 56).
Secondary outcome [10] 460415 0
Changes to low-density lipoprotein (LDL) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [10] 460415 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [11] 460416 0
Changes to triglyceride concentrations following adherence to a 28-day period of an ultra-processed food diet compared to habitual diet.
Timepoint [11] 460416 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [12] 460417 0
Changes to Aspartate transaminase (AST) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [12] 460417 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [13] 460418 0
Changes to Alanine transaminase (ALT) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [13] 460418 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [14] 460419 0
Changes to C-reactive protein (CRP) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [14] 460419 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [15] 460420 0
Change in Adiponectin under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [15] 460420 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [16] 460421 0
Change in active Ghrelin under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [16] 460421 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [17] 460422 0
Change in glucagon-like peptide-1 (GLP-1) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [17] 460422 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [18] 460423 0
Change in peptide YY (PYY) under conditions of an ultra-processed food diet compared to habitual diet.
Timepoint [18] 460423 0
Venous blood samples will be collected in a fasted state at visits 2–6 (Days 1, 14, 29, 43, 56).
Secondary outcome [19] 465168 0
Changes to heart rate variability.
Timepoint [19] 465168 0
Daily throughout the trial.

Eligibility
Key inclusion criteria
Participants will be recruited if they meet the following criteria:
• Healthy
• Aged 18-45 years
• Competitive athletes training > 12 h/week
• Ironman (3.8 km swim, 180 km bike, 42.2 km run) personal best times of < 11 h (males) and < 12 h (females).

Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Current musculoskeletal injuries that prevent you from training.
• Current/historical/family history of cardiovascular disease.
• Hypertension (>140/90 mmHg).
• Eating disorders/disordered eating.
• Regular alcohol (> 14 and > 7 standard drinks/week for males and females, respectively) / smoking use.
• Pregnant or breast feeding.
• Lipid-lowering, anti-hyperglycemic and incretin mimetic medication use.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
An a priori power analysis was conducted for a repeated measures ANOVA with five time points, with HDL-cholesterol as the primary outcome. Effect size was derived from the only existing comparable study, which reported a significant and substantial decline in HDL-cholesterol following a 14-day exclusive McDonalds diet in physically active young men (effect size: 0.96) [PMID: 28846611]. Using a within-subject correlation of 0.60 among repeated measures, GPower 3.1.9.7 (F tests; ANOVA: Repeated measures, within factors; e = 1) identified a required sample size of n = 12 to achieve 80% power at an alpha level of 0.05. Accounting for 30% attrition, we aim to recruit n = 16 participants, consistent with similar dietary intervention studies in athletic populations [PMID: 11591879, PMID: 32697366, PMID: 30305928, PMID: 40523229].

Data will be assessed for normality. Statistical model using a repeated measures ANOVA will be implemented, assessing HDL changes across the intervention. Covariate analysis using sex and training volume will also be explored. Significance will be set at p < 0.05.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321533 0
University
Name [1] 321533 0
Australian Catholic University, Mary Makillop Institure for Health Research.
Country [1] 321533 0
Australia
Primary sponsor type
University
Name
Australian Catholic University, Mary Makillop Institure for Health Research.
Address
Country
Australia
Secondary sponsor category [1] 324435 0
None
Name [1] 324435 0
Address [1] 324435 0
Country [1] 324435 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320068 0
ACU Human Research Ethics Committee
Ethics committee address [1] 320068 0
Ethics committee country [1] 320068 0
Australia
Date submitted for ethics approval [1] 320068 0
27/03/2026
Approval date [1] 320068 0
30/07/2026
Ethics approval number [1] 320068 0
2026-4749HC

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149322 0
Mr Kyle Alexander Dunlop
Address 149322 0
Centre for Human Performance & Metabolism, Level 3, 250 Victoria Parade, East Melbourne, VIC, 3002, Australia
Country 149322 0
Australia
Phone 149322 0
+61 425408039
Fax 149322 0
Email 149322 0
Contact person for public queries
Name 149323 0
Kyle Alexander Dunlop
Address 149323 0
Centre for Human Performance & Metabolism, Level 3, 250 Victoria Parade, East Melbourne, VIC, 3002, Australia
Country 149323 0
Australia
Phone 149323 0
+61 425408039
Fax 149323 0
Email 149323 0
Contact person for scientific queries
Name 149324 0
Kyle Alexander Dunlop
Address 149324 0
Centre for Human Performance & Metabolism, Level 3, 250 Victoria Parade, East Melbourne, VIC, 3002, Australia
Country 149324 0
Australia
Phone 149324 0
+61 425408039
Fax 149324 0
Email 149324 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Potentially identifiable data



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.